Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00031629 · ClinicalTrials.gov registry record · Phase 2
Combination Chemotherapy and Filgrastim or Pegfilgrastim in Treating Patients With Recurrent or Persistent Cancer of the Uterus
A Phase 2 study of Uterine Corpus Leiomyosarcoma and Recurrent Uterine Corpus Sarcoma, sponsored by Gynecologic Oncology Group.
- Completed
- Registry status
- Phase 2
- Development phase
- 51
- Enrollment target
- 1
- Study location
NCT00031629 is a Phase 2 study of Uterine Corpus Leiomyosarcoma and Recurrent Uterine Corpus Sarcoma that has completed, run by Gynecologic Oncology Group. The registered enrollment target is 51 participants. The trial reports 1 study location across 1 state.
The verdict
NCT00031629, a Phase 2 study of Uterine Corpus Leiomyosarcoma and Recurrent Uterine Corpus Sarcoma, has completed, sponsored by Gynecologic Oncology Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 51 participants
- Enrollment target
- 1
- Study location
Study Summary
Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. Colony-stimulating factors such as filgrastim or pegfilgrastim may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from the side effects of chemotherapy. This phase II trial is studying how well combination chemotherapy plus filgrastim or pegfilgrastim works in treating patients with recurrent or persistent cancer of the uterus.
Conditions Studied
Interventions
- DRUG Docetaxel
- BIOLOGICAL Filgrastim
- BIOLOGICAL Pegfilgrastim
- DRUG Gemcitabine Hydrochloride
Study Locations (1)
Pennsylvania
- Gynecologic Oncology Group - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2005-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00031629
The ClinicalTrials.gov registry entry for NCT00031629 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gynecologic Oncology Group, which has 154 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Uterine Corpus Leiomyosarcoma appearing as the primary indexed condition, and to 4 interventions - of which Docetaxel is the first listed.
NCT00031629 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00031629 about?
NCT00031629 is a clinical study titled "Combination Chemotherapy and Filgrastim or Pegfilgrastim in Treating Patients With Recurrent or Persistent Cancer of the Uterus". Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. Colony-stimulating factors such as filgrastim or pegfilgrastim may increase the number of immune cells found in bone marrow or peripher...
What is the current status of trial NCT00031629?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 51 participants. The study started on 2005-01.
What conditions does trial NCT00031629 study?
This clinical trial studies the following conditions: Uterine Corpus Leiomyosarcoma, Recurrent Uterine Corpus Sarcoma.
What interventions are being tested in trial NCT00031629?
The interventions under investigation include: Docetaxel (DRUG), Filgrastim (BIOLOGICAL), Pegfilgrastim (BIOLOGICAL), Gemcitabine Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00031629?
This trial is sponsored by Gynecologic Oncology Group, which has 154 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00031629 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Uterine Corpus Leiomyosarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Uterine Corpus Leiomyosarcoma
All registered trials for this condition
Recurrent Uterine Corpus Sarcoma
All registered trials for this condition
Pennsylvania
All trials with a study site in Pennsylvania
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.